Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Miami Beach, FL, US. The stock last traded at $0.49, up 2.62% on the session, giving a market capitalisation of $16.4M. On trailing twelve-month figures it carries a trailing P/E of -0.21, a net margin of 0.0%. Its beta of 0.29 implies it has historically moved less than the broad market.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Pasithea Therapeutics Corp. is most often compared with the following Healthcare names: